Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: relaytx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/26/2026 | $14.00 | Perform → Outperform | Oppenheimer |
| 12/12/2025 | $13.00 | Equal Weight → Overweight | Wells Fargo |
| 9/4/2025 | $15.00 | Buy | Guggenheim |
| 4/17/2025 | $4.00 | Equal Weight | Wells Fargo |
| 9/10/2024 | $20.00 | Buy | Goldman |
| 9/10/2024 | Outperform → Perform | Oppenheimer | |
| 9/10/2024 | $10.60 → $16.00 | Hold → Buy | Jefferies |
| 5/10/2024 | $15.00 | Equal Weight → Overweight | Barclays |
| 4/20/2023 | $12.50 | Underperform → Hold | Jefferies |
| 4/19/2023 | $29.00 | Outperform → Strong Buy | Raymond James |
8-K - Relay Therapeutics, Inc. (0001812364) (Filer)
424B5 - Relay Therapeutics, Inc. (0001812364) (Filer)
424B5 - Relay Therapeutics, Inc. (0001812364) (Filer)
8-K - Relay Therapeutics, Inc. (0001812364) (Filer)
SCHEDULE 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)
10-Q - Relay Therapeutics, Inc. (0001812364) (Filer)
8-K - Relay Therapeutics, Inc. (0001812364) (Filer)
DEFA14A - Relay Therapeutics, Inc. (0001812364) (Filer)
DEF 14A - Relay Therapeutics, Inc. (0001812364) (Filer)
8-K - Relay Therapeutics, Inc. (0001812364) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Oppenheimer upgraded Relay Therapeutics from Perform to Outperform and set a new price target of $14.00
Wells Fargo upgraded Relay Therapeutics from Equal Weight to Overweight and set a new price target of $13.00
Guggenheim resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $15.00
Wells Fargo initiated coverage of Relay Therapeutics with a rating of Equal Weight and set a new price target of $4.00
Goldman resumed coverage of Relay Therapeutics with a rating of Buy and set a new price target of $20.00
Oppenheimer downgraded Relay Therapeutics from Outperform to Perform
Jefferies upgraded Relay Therapeutics from Hold to Buy and set a new price target of $16.00 from $10.60 previously
Barclays upgraded Relay Therapeutics from Equal Weight to Overweight and set a new price target of $15.00
Jefferies upgraded Relay Therapeutics from Underperform to Hold and set a new price target of $12.50
Raymond James upgraded Relay Therapeutics from Outperform to Strong Buy and set a new price target of $29.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
4 - Relay Therapeutics, Inc. (0001812364) (Issuer)
Fastest customizable press release news feed in the world
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m. ETGoldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET The fireside chats will be webcast live and may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: https://
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 3,437,500 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $275 milli
CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today that it has commenced an underwritten public offering of $175 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Relay Therapeutics. Jefferies, TD Cowen, Goldman Sachs & Co. LLC and Guggenhei
Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported outcomes show 89% and 79% of patients achieved clinical improvement at week 12, respectively, and support the potential of zovegalisib to drive clinically meaningful benefit for patients Evaluation across a wide dose range confirms potential therapeutic window, with interim safety profile supportive of chronic dosing and no patients discontinuing treatment due to adverse events Expansion cohorts for adults and adolescents opened at 400mg once daily (QD) and 300mg BID;pediatric
FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase 3 dose in CDK4/6-experienced patients at ESMO TAT, demonstrating 11.1-month median PFS with similar efficacy in kinase and non-kinase mutations Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027 Initiated Phase 1/2 trial of RLY-8161, a NRAS-selective molecule, in patients with NRAS-mutant solid tumors Initial vascular anomalies clinical data conferenc
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report first quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Tuesday, May 5, 2026. About Relay Therapeutics Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics' Dynamo® platform integrates an array of leading-edge computation
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line); ORR is similar across kinase and non-kinase PIK3CA mutations Phase 3 frontline trial in endocrine sensitive patients expected to initiate in early 2027, subject to regulatory feedback Supply agreement in place with Pfizer to supply atirmociclib for the Phase 3 frontline trial Relay Therapeutics to host a conference call today, April 27, at 8:30am ET CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that initial clinical results and preclinical data for zovegalisib (RLY-2608) in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026, taking place May 19-22, 2026, in Philadelphia. The company anticipates reporting clinical data on approximately 20 efficacy-evaluable patients. Late Breaking Clinical Abstract:Abstract Title: Initial Results of Zoveg
400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Efficacy in patients with kinase and non-kinase domain mutations is similar, with median PFS of 11.2 and 11.0 months, respectively Safety and tolerability data are consistent with 600mg BID fasted data Zovegalisib has received FDA Breakthrough Therapy designation for the Phase 3 ReDiscover-2 trial population CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage, small molecule precision medicine company developing potential
LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current
Live finance-specific insights
Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported outcomes show 89% and 79% of patients achieved clinical improvement at week 12, respectively, and support the potential of zovegalisib to drive clinically meaningful benefit for patients Evaluation across a wide dose range confirms potential therapeutic window, with interim safety profile supportive of chronic dosing and no patients discontinuing treatment due to adverse events Expansion cohorts for adults and adolescents opened at 400mg once daily (QD) and 300mg BID;pediatric
FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase 3 dose in CDK4/6-experienced patients at ESMO TAT, demonstrating 11.1-month median PFS with similar efficacy in kinase and non-kinase mutations Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027 Initiated Phase 1/2 trial of RLY-8161, a NRAS-selective molecule, in patients with NRAS-mutant solid tumors Initial vascular anomalies clinical data conferenc
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line); ORR is similar across kinase and non-kinase PIK3CA mutations Phase 3 frontline trial in endocrine sensitive patients expected to initiate in early 2027, subject to regulatory feedback Supply agreement in place with Pfizer to supply atirmociclib for the Phase 3 frontline trial Relay Therapeutics to host a conference call today, April 27, at 8:30am ET CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib (CDK4-selective) initiated & ribociclib triplet combination ongoing Relay Therapeutics to host a conference call today, December 11, at 7am ET (6am CT) SAN ANTONIO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and expe
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer will be presented at the upcoming San Antonio Breast Cancer Symposium, taking place December 10-13, 2024. Details of the RLY-2608 + fulvestrant poster presentation are as follows:Abstract Title: PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3C
9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia Data support planned initiation of 2L pivotal study in 2025 Triplet combination with ribociclib expected to move into dose expansion in 1H 2025 & triplet combination with atirmociclib (CDK4) remains on track to start before year-end Relay Therapeutics to host a conference call today, September 9, at 8:00 a.m. ET CAMBRIDGE,
Interim data to be reported for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Conference call to be held Monday, September 9, at 8am ET CAMBRIDGE, Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced plans to host a conference call and webcast to report data for RLY-2608 600mg BID + fulvestrant in the ongoing ReDiscover trial in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer and next steps on Monda
35% ORR in patients with FGFR2 fusions (excluding CCA) & 40% ORR in patients with FGFR2-altered HR+/HER2- breast cancer RLY-4008 commercialization plans to focus on broader tumor agnostic opportunities Clinical focus on PI3Kα mutant selective programs, with plans to initiate RLY-2608 triplet combinations in HR+/HER2- breast cancer by YE 2023 Pipeline updates extend cash runway by 1 year into 2H2026 Relay Therapeutics to host a conference call today, October 12, at 5:30 p.m. ET BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and
CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that data for RLY-4008 (lirafugratinib) in patients with advanced FGFR2-altered solid tumors outside of cholangiocarcinoma will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023. Details of the oral presentation are as follows:Title: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients wi
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2023 financial results and corporate highlights after the close of market on Thursday, May 4, 2023. The company will not be conducting a teleconference in conjunction with its financial results press release. About Relay Therapeutics Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technol
Live Leadership Updates
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.
SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Section 32 announced today the closing of its fourth fund, raising approximately $740 million from returning and new investors. Investors in Fund 4 include leading philanthropic and non-profit organizations, educational endowments and foundations, and leaders from the technology and healthcare sectors. Section 32 Fund 4 will support companies across all stages that are pioneering innovations at the forefront of technology and healthcare. With the closing of its oversubscribed Fund 4 and to support its continued growth, Section 32 also announced the appointment of Nina Labatt to the role of Chief Operating Officer and Chief Financial Officer.
Murcko brings over 30 years of chemistry development in biotech experience to the synthetic biology startup Today, Octant, a therapeutics company integrating novel high-throughput experimental technologies with computation to solve complex challenges in drug discovery, announced the appointment of Mark Murcko as Strategic Advisor and Board Member. Murcko brings over three decades of industry experience, having been at the center of many transformational biotech efforts, most recently as founding CSO and Board Member of Dewpoint Therapeutics. Murcko is working closely with the company to scale Octant to its next phase of growth and further develop its chemistry platform. This press release
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appointment of Patrick Riley, Ph.D., as senior vice president of artificial intelligence. Dr. Riley is an industry expert in artificial intelligence and machine learning, bringing 15 years of experience from Google and extensive knowledge in applying these technologies to drug discovery. Dr. Riley will lead a computational team and report to group head, Pat Walters. "We are excited to welcome Patrick to our computational organi
This live feed shows all institutional transactions in real time.
SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)
SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)
SC 13G - Relay Therapeutics, Inc. (0001812364) (Subject)
SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)
SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)
SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)
SC 13G - Relay Therapeutics, Inc. (0001812364) (Subject)
SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)
SC 13G/A - Relay Therapeutics, Inc. (0001812364) (Subject)
SC 13G - Relay Therapeutics, Inc. (0001812364) (Subject)